Matthew Shaulis

Matthew Shaulis has served as Chief Commercial Officer and President of the U.S. affiliate, Hansa Biopharma Inc since March 2023. Prior to his role at Hansa Biopharma, Matthew gained over 20 years of US and international experience in the pharmaceutical industry in general management, global strategic and in-line marketing, sales management, business development, and product and indication launches. He held several senior executive roles at Pfizer Inc. (NYSE: PFE), including President of Inflammation & Immunology for International markets in Europe and Asia, President of Oncology for North America, and more recently as the Senior Vice President responsible for leading the company’s global commercial and medical go-to-market model transformation. Prior to that, Matthew served in various leadership roles at Teva Pharmaceutical Industries (NYSE: TEVA), Cephalon, Johnson & Johnson (LSE: JNJ), and Schering-Plough (now part of Merck & Co., Inc. (NYSE: MRK)). He holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Fuqua School of Business, Duke University, North Carolina. He was born in 1973.